Winicker-Norimed Medizinische Forschung
Winicker-Norimed Medizinische Forschung is recorded as a service provider in 6 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 6 of 6 trials · Latest update first
A Phase 3, multicenter, open-label, single-arm, extension study to evaluate the long-term safety and tolerability of cenerimod in adult subjects with moderate-to-severe systemic lupus erythematosus (SLE) on top of background therapy (OPUS OLE)
Sponsor Viatris Innovation GmbH
- Start (EU)
- Latest update
- Estimated end
Multi-center, double-blind, randomized, placebo-controlled, parallel-group, polysomnography, dosefinding study assessing the efficacy, safety, and pharmacokinetics of multiple-dose oral administration of daridorexant in pediatric subjects aged 10 to < 18 years with insomnia disorder
Sponsor Idorsia Pharmaceuticals Ltd.
- Start (EU)
- Latest update
- Estimated end
A multicenter rollover extension program (REP) to evaluate the long-term safety and tolerability of open label iptacopan in adult participants with primary IgA nephropathy who have completed a Novartis-sponsored iptacopan parent study in IgAN
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
Multi-center, double-blind, randomized, placebo-controlled, parallel-group study to evaluate the efficacy and safety of self-administered subcutaneous selatogrel for prevention of all-cause death and treatment of acute myocardial infarction in subjects with a recent history of acute myocardial infarction
Sponsor Viatris Innovation GmbH
- Start (EU)
- Latest update
- Estimated end
Phase 1/2 study evaluating genetically modified autologous T cells expressing a T-cell receptor recognizing a cancer/germline antigen as monotherapy or in combination with nivolumab in patients with recurrent and/or refractory solid tumors (ACTengine® IMA203-101)
Sponsor Immatics US Inc.
- Start (EU)
- Latest update
- Estimated end
A randomized, multicenter, open-label trial comparing the effectiveness of Inclisiran to bempedoic acid on LDL cholesterol (LDL-C) lowering in participants with atherosclerotic cardiovascular disease (VICTORION-CHALLENGE)
Sponsor Novartis Pharma GmbH
- Start (EU)
- Latest update
- Estimated end
- Not reported
Questions about this trial experience
What services are recorded for Winicker-Norimed Medizinische Forschung?
The 2026-10-09 snapshot links Winicker-Norimed Medizinische Forschung to 6 distinct CTIS trials. Recorded services include Clinical monitoring, Medical writing, Administrative Support, Data management, among 9 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Winicker-Norimed Medizinische Forschung?
The most frequently recorded therapeutic areas are Immunology, Rheumatology. Recorded phases include Phase 3. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Winicker-Norimed Medizinische Forschung conducted?
The linked trials record locations in 24 countries, including Germany, Spain, Bulgaria, Czechia, France. These are trial locations, not confirmed office locations or countries where Winicker-Norimed Medizinische Forschung delivered services.
What can this page tell me about Winicker-Norimed Medizinische Forschung's trial experience?
Browse 6 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Winicker-Norimed Medizinische Forschung. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Winicker-Norimed Medizinische Forschung GmbH